

DXRX – The Diagnostic Network[®]

Enabling the diagnostic industry to
extract more value from Precision
Medicine



DXRX

The Diagnostic Network[®]

by

Diaceutics

Better Testing, Better Treatment

Discover DXRX – The Diagnostic Network®

Imagine a vibrant marketplace where all stakeholders in Precision Medicine come to find trusted partners and collaborations in a secure, standardized way

With access to a pipeline of global diagnostic testing data on one secure platform

DXRX is an end-to-end solution for the development and commercialization of precision medicine diagnostics., from biomarker discovery to in-market test availability

Learn how the DXRX Network can enable your teams to:

- **Profile your organization** and capabilities on a secure platform for best-in-class partnering opportunities
- **Realize the** value of your test capabilities as a key driver in the delivery of better patient outcomes
- **Accelerate business development opportunities** using a streamlined, transparent process

What's inside

Our Expertise.....	1
The Potential of Precision Medicine.....	2
Solving An Industry Challenge.....	4
Discover the Network.....	7
Features and Benefits.....	10
Solutions and Services.....	13
DXRX Marketplace.....	14
DXRX Data.....	18
Learn More.....	22

Our Expertise


Our mission is to get every patient the treatment they deserve

- Diaceutics is a data analytics and end-to-end services provider
- We are enabled by DXRX – the world's first Diagnostic Network solution for the development and commercialization of Precision Medicine diagnostics
- We have worked on every Precision Medicine brought to market
- We are trusted by 36 of the world's leading pharma companies

We understand the real-world challenges faced by labs every day




The Growing Challenge And Potential Of Precision Medicine




40% of all FDA approvals in 2018 were for Precision Medicines with 1000 potential therapies in late phase of development

Up to 50%


of eligible patients don't get access to a Precision Medicine due to testing hurdles




It takes up to **4.5 years** for a biomarker test to be developed



It takes up to **3 years for over 70% of labs** to get ready to offer a new biomarker test




The Growing Challenge And Potential Of Precision Medicine



Solving An Industry Challenge

The 6 Barriers to Diagnostic Adoption Causing Patients to Be Missed



Solving an Industry Challenge

Case study: NSCLC testing and treatment landscape

Testing, Treatment and Data Analysis are all advancing in Non-Small-Cell Lung Cancer. [The Diagnostics 2020 Precision Medicine Report](#) analyses real-world hurdles in the NSCLC diagnostic landscape and explores an industry-wide solution to address an ecosystem which is under-delivering for patients.



~**80%** of PM educational investment by pharma is spent on the predictive biomarker phase



Today, Lab-developed tests comprise between **40% - 70%** of NSCLC testing



Today it can take up to **4.5 years** for a biomarker to reach an 80% testing rate among patients



Up to **50%** of eligible patients don't get access to a Precision Medicine due to hurdles in the ecosystem



Up to **30%** of the value of a PM treatment is delivered by the diagnostic test



The NSCLC testing market is predicted to grow in value from **\$5.3 to \$7.4bn** by 2025



“

“Given the richness of the data we have, Diaceutics has been uniquely positioned to identify that, as an industry, we have been getting it wrong when it comes to patient testing for precision medicines.

We believe that DXRX is the solution.”


Derek Hosty,
Head of Innovation,
Diaceutics

DXRX - The Diagnostic Network®

Leverage the **world's first diagnostic network** for Precision Medicine

The world's largest global flow of diagnostic testing data
integrating **2500+** laboratories into one secure network

Industry experience from working on every precision
medicine brought to market




Recent Network Partnerships



Quality in Control



UK NEQAS



Collaborate with a global panel of industry KOLs in Precision Medicine diagnostics



Dr Anthony Magliocco,
CEO,
Protean BioDiagnostics Inc.,
US



Markus Eckstein,
MD,
University Hospital Erlangen,
Germany



Kenneth J. Bloom,
CMO,
Invicro and Ambry
Genetics,
US



Keith Kerr,
Professor and Consultant
Pathologist,
Aberdeen University School
of Medicine,
Scotland



Dr Fotios Loupakis,
Medical Oncologist,
Institute of Oncology at Veneto,
Italy

Features and Benefits





Be part of the world's first diagnostic network for precision medicine to get every patient the treatment they deserve

Join a global movement with key stakeholders in precision medicine to integrate seamless diagnostic testing at every stage of the development and commercialization journey

Profile your organization and capabilities on a secure platform for best-in-class partnering opportunities

DXRX enables diagnostic companies to profile their organization, technology and capabilities in a secure, standardized way to facilitate best-in-class collaborations with the world's leading pharmaceutical companies





Realize the value of your test capabilities as a key driver in the delivery of better patient outcomes

Interact with pharmaceutical companies earlier in the development phase to enhance the value delivered by your test throughout commercialization

Accelerate business development opportunities using a streamlined, transparent process

Respond to and engage with RFPs which are aligned with your organization's capabilities using a standardized partner selection process



Solutions and Services



Discover DXRX Marketplace

DXRX enables a vibrant marketplace where all stakeholders in Precision Medicine come to find trusted partners for collaboration on precision medicine diagnostics in a secure, standardized way





“

“I am honored to be part of what is very much an unprecedented approach to bringing stakeholders on to one secure platform to collaborate around diagnostic testing.

I see there being a huge appetite for this technology not only with pharma, labs and diagnostic companies but also with clinicians and any service provider involved in the process of getting patients treated.”



Kenneth J. Bloom,
CMO, Invicro and Ambry Genetics,
DXRX Network Advisor,
US

Marketplace Collaborations

A DXRX collaboration is an opportunity for multiple stakeholders to work together to solve real-world testing challenges ensuring every patient gets the treatment they deserve

- Profile your organization and capabilities on a secure platform for best in class partnering opportunities
- Accelerate business development opportunities using a streamlined, transparent process

Realize the value of your test capabilities as a key driver in the delivery of better patient outcomes



Discover live DXRX collaborations [here](#)



“


“The era of launching a therapy with a single companion diagnostic partner is behind us. We need to consider the global needs of our patients and the regional restrictions commonly faced. This calls for pharma to think beyond a one-size-fits-all approach and embrace the democratisation of testing.”

Peter Keeling,
Chief Executive Officer,
Diaceutics

Discover the Data

DXRX integrates a global flow of diagnostic testing data into one secure platform

The network has been purpose built to provide unrivalled access to rich data analytics for all stakeholders in precision medicine



DXRX Data

DXRX provides access to the worlds largest diagnostic testing data repository combining multiple sources of information to build a complete picture of a patient's diagnostic journey.

Our lab-derived data is enhanced with diagnostic, claims, registry and demographic data. Every diagnostic event within the data repository has been labelled by our team of clinical experts, this is particularly required for the lab data which is inherently lacking standardization.

Expert data labeling allows for seamless integration across datasets and enables Diaceutics to use innovative algorithms to derive insights.



365 million
de-identified patient records



2500+
Laboratories globally



35
countries



Average 4.3 years'
longitudinal history



670,000
referring physicians



9,500
payors globally



47
disease diagnostic
pathways mapped (DDP)



Data available from
2011

Data Protection, Security and Compliance

Data protection is extremely important to Diaceutics and we always aim to provide clear and transparent information about how its use Personal Data.

Diaceutics' aim is not to be intrusive, but to provide genuine collaboration opportunities for all stakeholders to work together to solve real-world testing challenges, ensuring every patient gets the treatment they deserve. Diaceutics have robust measures and procedures in place to minimize the risk of unauthorized access to the DXRX Platform and to keep it secure.



DXRX is hosted on secure and scalable AWS (Amazon Web Services) infrastructure.

It has been security tested by third party cyber security experts to ensure best practices are adopted and known vulnerabilities are addressed.

DXRX has been privacy assessed by our Legal team to ensure compliance with applicable laws and regulations on data privacy and security.



“

"Our Experts have worked on every precision medicine brought to market which places Diaceutics in a unique position to guide innovative pharmaceutical companies in the integration of best in class precision medicine diagnostics into their business model.

We combine global expertise and local insight to help our partners turn bold vision into long term value."

Susanne Munksted,
Chief Precision Officer,
Diaceutics

Learn More

Talk to us about your diagnostic development and commercialization needs now at marketing@diaceutics.com

